Shuttle Pharmaceuticals Holding (SHPH) Stock Price & How to Invest

Shuttle Pharmaceuticals Holdings, Inc. began as a clinical-stage biopharmaceutical company spun out of research at Georgetown University, focused on radiation therapy and drugs that make tumors more sensitive to radiation. Its lead candidate, ropidoxuridine (IPdR), was an oral radiation sensitizer being studied in a Phase 2 trial for newly diagnosed glioblastoma, and it carried FDA Orphan Drug Designation. For most of its public life the company generated no product revenue and funded operations through equity raises, the typical profile of an early-stage biotech whose value depended on clinical trial outcomes.

In November 2025 the company changed direction. It acquired and integrated Molecule.ai, an artificial-intelligence platform for molecular discovery and early-stage drug development, and disclosed a plan to discontinue and wind down the ropidoxuridine clinical trials. As of its latest annual report the company described a net loss of roughly $11.7 million, no revenue, and a working-capital deficit, and management concluded there was substantial doubt about its ability to continue as a going concern. Through 2025 and into 2026 Shuttle completed multiple financings, including a March 2026 underwritten offering and a roughly $9.55 million PIPE, to shore up its balance sheet and stay compliant with Nasdaq listing requirements. The stock has seen sharp, volatile trading. In short, the investment picture is a highly speculative micro-cap making an unproven pivot from clinical research toward AI-driven drug discovery, with survival dependent on continued outside financing.

The risks here are severe and should not be understated. Management has flagged substantial doubt about the company's ability to continue as a going concern, with no revenue, ongoing cash burn, and a working-capital deficit, meaning survival depends on raising more outside money. That financing is highly dilutive: repeated stock offerings, PIPE deals, convertible preferred shares, and warrants can sharply increase the share count and pressure the price. The core business strategy is unproven, having just pivoted from clinical trials to an AI platform that has yet to demonstrate meaningful, recurring revenue. As a Nasdaq micro-cap, the stock has faced listing-compliance issues (such as minimum stockholders' equity) and has traded with extreme volatility and speculative day-trader interest. Discontinuing the lead drug also removes the original clinical catalyst that first drew investors. This is a small, speculative security where a total loss is a real possibility.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Shuttle Pharmaceuticals Holding's investor relations page or your broker.

• Revenue trend: No meaningful product revenue historically; the new Molecule.ai platform is early and any commercial revenue is unproven
• Profitability: Deeply unprofitable; the latest annual report described a net loss of roughly $11.7 million with ongoing cash burn
• Balance sheet: Weak; management flagged a working-capital deficit and substantial doubt about the company's ability to continue as a going concern, offset only by repeated capital raises
• Valuation: A speculative micro-cap valued on narrative and potential rather than earnings or revenue; traditional multiples do not meaningfully apply
• Analyst sentiment: Thin coverage; the stock trades largely on news, financings, and speculative interest rather than established analyst estimates
• Dilution risk: High; underwritten offerings, a roughly $9.55 million PIPE, convertible preferred stock, and warrants can materially increase the share count

These characterizations are directional and tied to the asOf date, not precise live figures. Micro-cap financials like Shuttle's change quickly, especially through frequent financings that alter cash balances and share counts, and the recent pivot means historical numbers may not reflect the current business. Going-concern language is a serious signal that the company needs continued outside capital to operate. Always verify the latest cash position, share count, revenue, losses, and Nasdaq compliance status directly from Shuttle's most recent SEC filings and a live quote before drawing any conclusions.

There are three common ways to get SHPH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SHPH sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SHPH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Shuttle Pharmaceuticals is a pre-revenue micro-cap that pivoted from clinical cancer research to an AI drug-discovery platform (Molecule.ai) while discontinuing its lead drug. With no revenue, going-concern doubt, and repeated dilutive raises, it is a highly speculative bet on an unproven strategy shift, not an established business.